{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T15:22:13Z","timestamp":1649172133282},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,6,10]],"date-time":"2012-06-10T00:00:00Z","timestamp":1339286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s12328-012-0314-5","type":"journal-article","created":{"date-parts":[[2012,6,10]],"date-time":"2012-06-10T04:42:55Z","timestamp":1339303375000},"page":"302-306","source":"Crossref","is-referenced-by-count":4,"title":["Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn\u2019s disease accompanied by chronic myeloid leukemia"],"prefix":"10.1007","volume":"5","author":[{"given":"Tsutomu","family":"Mizoshita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tanida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Ebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Joh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,10]]},"reference":[{"key":"314_CR1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","volume":"40","author":"SJ Deventer Van","year":"1997","unstructured":"Van Deventer SJ. Tumour necrosis factor and Crohn\u2019s disease. Gut. 1997;40:443\u20138.","journal-title":"Gut"},{"key":"314_CR2","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323\u201333 (quiz 591).","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"314_CR3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/00365520600979369","volume":"42","author":"T Ljung","year":"2007","unstructured":"Ljung T, Thomsen OO, Vatn M, et al. Granulocyte, monocyte\/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol. 2007;42:221\u20137.","journal-title":"Scand J Gastroenterol"},{"key":"314_CR4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1023\/B:DDAS.0000026299.43792.ae","volume":"49","author":"Y Suzuki","year":"2004","unstructured":"Suzuki Y, Yoshimura N, Saniabadi AR, et al. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004;49:565\u201371.","journal-title":"Dig Dis Sci"},{"key":"314_CR5","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1038\/ajg.2009.453","volume":"104","author":"A Sakuraba","year":"2009","unstructured":"Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990\u20135.","journal-title":"Am J Gastroenterol"},{"key":"314_CR6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"314_CR7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"314_CR8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94:1765\u20139.","journal-title":"Br J Cancer"},{"key":"314_CR9","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1007\/s10620-005-2966-1","volume":"50","author":"JA Makarem","year":"2005","unstructured":"Makarem JA, Otrock ZK, Sharara AI, et al. Crohn\u2019s disease in leukemia: report of a case, with a review of the literature. Dig Dis Sci. 2005;50:1950.","journal-title":"Dig Dis Sci"},{"key":"314_CR10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)90191-9","volume":"347","author":"K Hatake","year":"1996","unstructured":"Hatake K, Tanaka M, Muroi K, et al. Leukaemia risk in Crohn\u2019s disease. Lancet. 1996;347:1049\u201350.","journal-title":"Lancet"},{"key":"314_CR11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ibd.3780050206","volume":"5","author":"GC Harewood","year":"1999","unstructured":"Harewood GC, Loftus EV Jr, Tefferi A, et al. Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis. 1999;5:98\u2013103.","journal-title":"Inflamm Bowel Dis"},{"key":"314_CR12","unstructured":"Mir Madjlessi SH, Farmer RG, Weick JK. Inflammatory bowel disease and leukemia. A report of seven cases of leukemia in ulcerative colitis and Crohn\u2019s disease and review of the literature. Dig Dis Sci. 1986;31:1025\u201331."},{"key":"314_CR13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00004836-199106000-00015","volume":"13","author":"S Orii","year":"1991","unstructured":"Orii S, Sugai T, Nakano O, et al. Acute promyelocytic leukemia in Crohn\u2019s disease. Case report and review of the literature. J Clin Gastroenterol. 1991;13:325\u20137.","journal-title":"J Clin Gastroenterol"},{"key":"314_CR14","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617\u201325.","journal-title":"Lancet"},{"key":"314_CR15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1744-9987.2011.00970.x","volume":"15","author":"K Nagase","year":"2011","unstructured":"Nagase K, Fukunaga K, Kashiwamura S, et al. Immunoregulatory effects of adsorptive granulocyte and monocyte apheresis in patients with drug refractory Crohn\u2019s disease. Ther Apher Dial. 2011;15:367\u201373.","journal-title":"Ther Apher Dial"},{"key":"314_CR16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1744-9987.1998.tb00091.x","volume":"2","author":"N Kashiwagi","year":"1998","unstructured":"Kashiwagi N, Hirata I, Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher. 1998;2:134\u201341.","journal-title":"Ther Apher"},{"key":"314_CR17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1526-0968.2003.00012.x","volume":"7","author":"AR Saniabadi","year":"2003","unstructured":"Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7:48\u201359.","journal-title":"Ther Apher Dial"},{"key":"314_CR18","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s00535-004-1465-z","volume":"39","author":"Y Fukuda","year":"2004","unstructured":"Fukuda Y, Matsui T, Suzuki Y, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn\u2019s disease: an open multicenter prospective study. J Gastroenterol. 2004;39:1158\u201364.","journal-title":"J Gastroenterol"},{"key":"314_CR19","first-page":"511","volume":"98","author":"T Matsui","year":"2003","unstructured":"Matsui T, Nishimura T, Matake H, et al. Granulocytapheresis for Crohn\u2019s disease: a report on seven refractory patients. Am J Gastroenterol. 2003;98:511\u20132.","journal-title":"Am J Gastroenterol"},{"key":"314_CR20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2169\/internalmedicine.51.6801","volume":"51","author":"K Ozeki","year":"2012","unstructured":"Ozeki K, Tanida S, Mizushima T, et al. Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis induced clinical remission in a Crohn\u2019s disease patient with the loss of response to scheduled adalimumab maintenance therapy: a case report. Intern Med. 2012;51:595\u20139.","journal-title":"Intern Med"},{"key":"314_CR21","doi-asserted-by":"crossref","unstructured":"D\u2019Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199\u2013212 (quiz 213).","DOI":"10.1038\/ajg.2010.392"},{"key":"314_CR22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ibd.20169","volume":"13","author":"JR Rosh","year":"2007","unstructured":"Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn\u2019s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024\u201330.","journal-title":"Inflamm Bowel Dis"},{"key":"314_CR23","doi-asserted-by":"crossref","unstructured":"Gonzalez Carro P, Perez Roldan F, Roncero Garcia Escribano O, et al. Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn\u2019s disease. J Clin Apher. 2006;21:249\u201351.","DOI":"10.1002\/jca.20093"},{"key":"314_CR24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/jca.20242","volume":"25","author":"K Fukunaga","year":"2010","unstructured":"Fukunaga K, Yokoyama Y, Kamikozuru K, et al. Selective depletion of peripheral granulocyte\/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn\u2019s disease. J Clin Apher. 2010;25:226\u20138.","journal-title":"J Clin Apher"},{"key":"314_CR25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/ard.2004.021378","volume":"64","author":"F Broussais","year":"2005","unstructured":"Broussais F, Kawashima M, Marotte H, et al. Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab. Ann Rheum Dis. 2005;64:509\u201310.","journal-title":"Ann Rheum Dis"},{"key":"314_CR26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.leukres.2006.03.023","volume":"31","author":"H Mittre","year":"2007","unstructured":"Mittre H, Marcelli C, Leporrier M. Infliximab in chronic myelogenous leukemia. Leuk Res. 2007;31:418\u20139.","journal-title":"Leuk Res"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-012-0314-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-012-0314-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-012-0314-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T13:09:42Z","timestamp":1561813782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-012-0314-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1007\/s12328-012-0314-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,10]]}}}